middle.news
Syntara’s Parkinson’s Drug Shows Motor Improvement After Treatment Stops
1:26pm on Friday 30th of October, 2026 AEDT
•
Biotechnology
Read Story
Syntara’s Parkinson’s Drug Shows Motor Improvement After Treatment Stops
1:26pm on Friday 30th of October, 2026 AEDT
Key Points
SNT-4728 reduced putamen inflammation and improved clinician-assessed motor signs after treatment ceased
AZALOX advanced to its final Phase 1b dose cohort without dose-limiting toxicities
SNT-9465 scar study expanded to 30 participants, with results expected in Q1 2027
A$4.7 million R&D tax incentive helped lift cash to A$14.06 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Syntara (ASX:SNT)
OPEN ARTICLE